LB Pharmaceuticals Inc
LBRX
$14.90
-$0.61-3.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.73% | 174.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -80.08% | -68.16% | |||
| Operating Income | 80.08% | 68.16% | |||
| Income Before Tax | 81.63% | 68.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 81.63% | 68.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.63% | 68.50% | |||
| EBIT | 80.08% | 68.16% | |||
| EBITDA | 80.37% | 68.62% | |||
| EPS Basic | 68.77% | 68.77% | |||
| Normalized Basic EPS | -- | 70.65% | |||
| EPS Diluted | 68.77% | 68.77% | |||
| Normalized Diluted EPS | -- | 70.65% | |||
| Average Basic Shares Outstanding | -- | 0.88% | |||
| Average Diluted Shares Outstanding | 0.88% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||